Full Text View
Tabular View
No Study Results Posted
Related Studies
The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin
This study has been completed.
Study NCT00031343   Information provided by National Institutes of Health Clinical Center (CC)
First Received: March 2, 2002   Last Updated: March 3, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
HIV Infections
Hepatitis C
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
Hepatitis
Infection
More general conditions related to this trial
Digestive System Diseases
Flaviviridae Infections
Hepatitis, Viral, Human
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Liver Diseases
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Additional drug interventions recognized in this trial
Peginterferon alfa-2b
More general drug interventions related to this trial
Anti-Infective Agents
Antiviral Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
National Institute of Allergy and Infectious Diseases (NIAID)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services